To identify the treatment cohort, the KRD was searched for all patients with 1 claim for semaglutide 2.4 mg between June 15, 2021 and July 31, 2022
Second, dosing protocols in the community are all over the place
Similar content being viewed by others Digital Features This article is published with digital features, including an infographic, to facilitate understanding of the article
Areas typically treated with injectables include the temples, areas around the eyes, the cheeks, lips, and jawline
[9] [2] According to NICE guidance, patients with confirmed B12 deficiency and neurological involvement typically require more frequent initial dosing (alternate-day injections) until symptom improvement occurs
In addition, GLP-1R stimulation activates insulin signaling pathways and regulates gene expression, decreasing systemic insulin resistance and brain insulin resistance in patients with AD (Dahiya et al., 2025)